Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Shares Issued (2016 - 2024)

Historic Shares Issued for Guided Therapeutics (GTHP) over the last 13 years, with Q4 2024 value amounting to $535000.0.

  • Guided Therapeutics' Shares Issued rose 12199.17% to $535000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $835000.0, marking a year-over-year increase of 9151.38%. This contributed to the annual value of $835000.0 for FY2024, which is 9151.38% up from last year.
  • Per Guided Therapeutics' latest filing, its Shares Issued stood at $535000.0 for Q4 2024, which was up 12199.17% from $300000.0 recorded in Q3 2024.
  • In the past 5 years, Guided Therapeutics' Shares Issued ranged from a high of $1.8 million in Q2 2021 and a low of -$1.8 million during Q3 2021
  • In the last 5 years, Guided Therapeutics' Shares Issued had a median value of $195000.0 in 2023 and averaged $204846.2.
  • In the last 5 years, Guided Therapeutics' Shares Issued surged by 692000.0% in 2021 and then plummeted by 9259.26% in 2022.
  • Quarter analysis of 5 years shows Guided Therapeutics' Shares Issued stood at -$128000.0 in 2020, then crashed by 1271.09% to -$1.8 million in 2021, then skyrocketed by 99.77% to -$4000.0 in 2022, then skyrocketed by 6125.0% to $241000.0 in 2023, then skyrocketed by 121.99% to $535000.0 in 2024.
  • Its Shares Issued stands at $535000.0 for Q4 2024, versus $300000.0 for Q3 2024 and $241000.0 for Q4 2023.